These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

450 related items for PubMed ID: 16313338

  • 1. Osteoclast precursors, RANKL/RANK, and immunology.
    Xing L, Schwarz EM, Boyce BF.
    Immunol Rev; 2005 Dec; 208():19-29. PubMed ID: 16313338
    [Abstract] [Full Text] [Related]

  • 2. Osteoclast precursors: cytokine-stimulated immunomodulators of inflammatory bone disease.
    Boyce BF, Schwarz EM, Xing L.
    Curr Opin Rheumatol; 2006 Jul; 18(4):427-32. PubMed ID: 16763465
    [Abstract] [Full Text] [Related]

  • 3. RANK signaling is not required for TNFalpha-mediated increase in CD11(hi) osteoclast precursors but is essential for mature osteoclast formation in TNFalpha-mediated inflammatory arthritis.
    Li P, Schwarz EM, O'Keefe RJ, Ma L, Boyce BF, Xing L.
    J Bone Miner Res; 2004 Feb; 19(2):207-13. PubMed ID: 14969390
    [Abstract] [Full Text] [Related]

  • 4. Regulation of vascular calcification by osteoclast regulatory factors RANKL and osteoprotegerin.
    Collin-Osdoby P.
    Circ Res; 2004 Nov 26; 95(11):1046-57. PubMed ID: 15564564
    [Abstract] [Full Text] [Related]

  • 5. Rheumatic diseases: the effects of inflammation on bone.
    Walsh NC, Crotti TN, Goldring SR, Gravallese EM.
    Immunol Rev; 2005 Dec 26; 208():228-51. PubMed ID: 16313352
    [Abstract] [Full Text] [Related]

  • 6. Anti-RANKL therapy for inflammatory bone disorders: Mechanisms and potential clinical applications.
    Anandarajah AP, Schwarz EM.
    J Cell Biochem; 2006 Feb 01; 97(2):226-32. PubMed ID: 16240334
    [Abstract] [Full Text] [Related]

  • 7. Role of RANKL in physiological and pathological bone resorption and therapeutics targeting the RANKL-RANK signaling system.
    Tanaka S, Nakamura K, Takahasi N, Suda T.
    Immunol Rev; 2005 Dec 01; 208():30-49. PubMed ID: 16313339
    [Abstract] [Full Text] [Related]

  • 8. New insight in the mechanism of osteoclast activation and formation in multiple myeloma: focus on the receptor activator of NF-kappaB ligand (RANKL).
    Giuliani N, Colla S, Rizzoli V.
    Exp Hematol; 2004 Aug 01; 32(8):685-91. PubMed ID: 15308315
    [Abstract] [Full Text] [Related]

  • 9. TNF receptor type 1 regulates RANK ligand expression by stromal cells and modulates osteoclastogenesis.
    Abu-Amer Y, Abbas S, Hirayama T.
    J Cell Biochem; 2004 Nov 15; 93(5):980-9. PubMed ID: 15389885
    [Abstract] [Full Text] [Related]

  • 10. Arthroplasty membrane-derived fibroblasts directly induce osteoclast formation and osteolysis in aseptic loosening.
    Sabokbar A, Itonaga I, Sun SG, Kudo O, Athanasou NA.
    J Orthop Res; 2005 May 15; 23(3):511-9. PubMed ID: 15885469
    [Abstract] [Full Text] [Related]

  • 11. Interactive effect of interleukin-6 and prostaglandin E2 on osteoclastogenesis via the OPG/RANKL/RANK system.
    Liu XH, Kirschenbaum A, Yao S, Levine AC.
    Ann N Y Acad Sci; 2006 Apr 15; 1068():225-33. PubMed ID: 16831922
    [Abstract] [Full Text] [Related]

  • 12. Osteoprotegerin and inflammation.
    Saidenberg Kermanac'h N, Bessis N, Cohen-Solal M, De Vernejoul MC, Boissier MC.
    Eur Cytokine Netw; 2002 Apr 15; 13(2):144-53. PubMed ID: 12101070
    [Abstract] [Full Text] [Related]

  • 13. RANKing intracellular signaling in osteoclasts.
    Feng X.
    IUBMB Life; 2005 Jun 15; 57(6):389-95. PubMed ID: 16012047
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. RANKL protein is expressed at the pannus-bone interface at sites of articular bone erosion in rheumatoid arthritis.
    Pettit AR, Walsh NC, Manning C, Goldring SR, Gravallese EM.
    Rheumatology (Oxford); 2006 Sep 15; 45(9):1068-76. PubMed ID: 16490750
    [Abstract] [Full Text] [Related]

  • 16. LIGHT (TNFSF14), a novel mediator of bone resorption, is elevated in rheumatoid arthritis.
    Edwards JR, Sun SG, Locklin R, Shipman CM, Adamopoulos IE, Athanasou NA, Sabokbar A.
    Arthritis Rheum; 2006 May 15; 54(5):1451-62. PubMed ID: 16649193
    [Abstract] [Full Text] [Related]

  • 17. Osteoclast differentiation and bone resorption in multicentric reticulohistiocytosis.
    Adamopoulos IE, Wordsworth PB, Edwards JR, Ferguson DJ, Athanasou NA.
    Hum Pathol; 2006 Sep 15; 37(9):1176-85. PubMed ID: 16938523
    [Abstract] [Full Text] [Related]

  • 18. Antioxidant alpha-lipoic acid inhibits osteoclast differentiation by reducing nuclear factor-kappaB DNA binding and prevents in vivo bone resorption induced by receptor activator of nuclear factor-kappaB ligand and tumor necrosis factor-alpha.
    Kim HJ, Chang EJ, Kim HM, Lee SB, Kim HD, Su Kim G, Kim HH.
    Free Radic Biol Med; 2006 May 01; 40(9):1483-93. PubMed ID: 16632109
    [Abstract] [Full Text] [Related]

  • 19. The role of the immune system in the pathophysiology of osteoporosis.
    Clowes JA, Riggs BL, Khosla S.
    Immunol Rev; 2005 Dec 01; 208():207-27. PubMed ID: 16313351
    [Abstract] [Full Text] [Related]

  • 20. Crystal structure of RANK ligand involved in bone metabolism.
    Ito S, Hata T.
    Vitam Horm; 2004 Dec 01; 67():19-33. PubMed ID: 15110169
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 23.